Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis
- Jesse D. Kirkpatrick ,
- Ava P. Soleimany ,
- Jaideep S. Dudani ,
- Heng-Jia Liu ,
- Hilaire C. Lam ,
- Carmen Priolo ,
- Elizabeth P. Henske ,
- Sangeeta N. Bhatia
The European Respiratory Journal | , Vol 59
Biomarkers of disease progression and treatment response are urgently needed for patients with lymphangioleiomyomatosis (LAM). Activity-based nanosensors, an emerging biosensor class, detect dysregulated proteases in vivo and release a reporter to provide a urinary readout of disease. Because proteases are dysregulated in LAM and may directly contribute to lung function decline, activity-based nanosensors may enable quantitative, real-time monitoring of LAM progression and treatment response. We aimed to assess the diagnostic utility of activity-based nanosensors in a pre-clinical model of pulmonary LAM.